News

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Asian individuals with out-of-hospital cardiac arrest have similar rates of bystander cardiopulmonary resuscitation as White individuals, but have lower survival rates, according to a new study.

Dr. Mikhail Kosiborod presented on the benefits of a cardiometabolic center of excellence for patients with cardiometabolic diseases at the ADA conference in San Diego.

In a new analysis, researchers looked at how older patients in the ISCHEMIA trial responded to invasive strategy compared with more conservative management.

KCTV talked to one local colon cancer survivor and Dr. Robert Amajoyi about the importance of screenings and when to start.

Dr. Sanjaya Gupta, electrophysiologist at Saint Luke's Mid America Heart Institute, talks with KCTV about risk factors and new treatment available at Saint Luke's Atrial Fibrillation Clinic.

Rehospitalization after aortic valve replacement (AVR) is associated with an increased risk of patient mortality, according to new research.

After being diagnosed with Stage 3 breast cancer and undergoing chemotherapy and radiation treatments, Jesse found her heart was failing from side effects of chemotherapy.

When Maribeth Kammert first learned she had cancer in 2015, her world came to a stop. It was early stage breast cancer. “I was at Beauty Brands with my mom when I got the call. I went into the bathroom because I didn’t know how I would react. I didn’t cry,” said Maribeth. “I just had this instinct that I was going to take care of it, and God was going to take care of me. And if the outcome wasn’t what I wanted, I’d be okay with that.”